Hua Medicine (HK:2552) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hua Medicine has announced plans to take over the commercialization of its diabetes treatment drug, HuaTangNing, from Bayer in China effective January 1, 2025. This strategic move follows significant milestones such as its approval by China’s National Medical Products Administration and its listing in the National Reimbursement Drug List. The company is exploring potential new partnerships to ensure uninterrupted sales and expand its market presence.
For further insights into HK:2552 stock, check out TipRanks’ Stock Analysis page.
